The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase I/II trial of MEK162 in combination with gemcitabine (G) and cisplatin (C) for patients (pts) with untreated advanced biliary cancer (ABC).
 
Maeve Aine Lowery
Consulting or Advisory Role - Agios; Celgene
 
Eileen Mary O'Reilly
Consulting or Advisory Role - Aduro Biotech; Astellas Pharma (I); Celgene; Celsion (I); Cipla; Exelixis (I); Gilead Sciences; Hexal (I); IntegraGen (I); Jennerex (I); Lilly (I); MedImmune; Merrimack; Novartis (I); Pharmacyclics; Sanofi; Silenseed; Vicus Therapeutics
Research Funding - AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Clovis Oncology (Inst); Immunomedics (Inst); Incyte (Inst); Momenta Pharmaceuticals (Inst); Myriad Genetics (Inst); OncoMed (Inst); Polaris (Inst); Sanofi (Inst)
 
James J. Harding
No Relationships to Disclose
 
Kenneth H. Yu
Consulting or Advisory Role - Celgene; Merck Serono; Merrimack
 
Andrea Cercek
No Relationships to Disclose
 
Ellen Hollywood
No Relationships to Disclose
 
Erica Salehi
No Relationships to Disclose
 
Ezra Margona
No Relationships to Disclose
 
Mikaela Bradley
No Relationships to Disclose
 
Trevor Witter
No Relationships to Disclose
 
Scott R. Gerst
No Relationships to Disclose
 
Marinela Capanu
No Relationships to Disclose
 
Leonard Saltz
Consulting or Advisory Role - Abbvie; Lilly; McNeil PPC (I); Roche/Genentech
Research Funding - Taiho Pharmaceutical
 
Ghassan K. Abou-Alfa
Consulting or Advisory Role - Aduro Biotech (I); Agios; Array BioPharma (I); ASLAN Pharmaceuticals; Astellas Pharma; Bayer; Blueprint Medicines; Boston Scientific; Bristol-Myers Squibb (I); CASI Pharmaceuticals; Celgene; Celgene (I); Celsion; Delcath Systems; Eisai; EMD Serono (I); Gilead Sciences (I); Halozyme (I); IntegraGen; Ipsen; Janssen (I); Merck Serono; Merrimack; Merrimack (I); Momenta Pharmaceuticals (I); New B Innovation; Newlink Genetics (I); Onxeo; Opsona Therapeutics (I); Pfizer (I); Roche; Sanofi (I); SERVIER; Silenseed (I); Sillajen; Sirtex Medical; VAXIMM (I); Vicus Therapeutics; Vicus Therapeutics (I); Westhaven
Research Funding - Amgen (Inst); Bayer (Inst); CASI Pharmaceuticals (Inst); Chugai Pharma (Inst); Exelixis (Inst); Genentech (Inst); MedImmune (Inst); Polaris (Inst); Roche (Inst); Vicus Therapeutics (Inst)
Travel, Accommodations, Expenses - Polaris